Bibliografía del artículo
1. World Health Organization. COVID-19 Weekly Epidemiological Update 22. World Heal Organ 2021 (January):1-3. [Consultado 12 jun 2021]. Disponible en: https://www.who.int/docs/default-source/coronaviruse/situation-reports/weekly epidemiological update 22.pdf.
2. Torner N. Collateral effects of Covid-19 pandemic emergency response on world-wideimmunizations. Vacunas 21:73-5, 2020.
3. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges increating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet 396:1614-6, 2020.
4. COVID-19 vaccination and prioritization strategies in the EU/EEA [consultado 14 Feb 2021] Disponible en: https://www.ecdc.europa.eu/en/publications- data/covid-19-vaccination-and-prioritisation-strategies-eueea.
5. Ministerio de Sanidad, Consumo y Bienestar Social - Profesionales - Estrategia de vacunacio?n COVID-19 en España [consultado 14 Feb 2021] Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/vacunaCovid19.htm.
6. Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403-16, 2021. PMID:33378609 https://doi.org/10.1056/ NEJMoa2035389
7. Eyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 20:615-32, 2020.
8. Casasa I, Mena G. La vacunación de la COVID-19. Medicina Clínica 56:500-502, 2021. www.e lsevier.es/medicinaclinicaEditorialThe COVID-19 vaccination.
9. Guljaš S, Bosnic Z, Salha T, Berecki M, Dupan ZK, Rudan S. Lack of informations about COVID-19 vaccine: from implications to intervention for supporting public health communications in COVID-19 pandemic. Int J Environ Res Public Health 18:6141, 2021.
10. Freeman D, Loe BS, Yu LM, Freeman J, Chadwick A, Vaccari C, Shanyin M. Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial. Lancet Public Health 6:e416-27, 2021. https://doi.org/10.1016/ S2468-2667(21)00096-7.
11. Paltiel AD, Zheng A, Schwartz JL. Speed versus efficacy: quantifying potential tradeoffs in covid-19 vaccine deployment. Annals of Internal Medicine doi:10.7326/M20-7866.
12. Adoff J, Gray G, Vandebosch A, et al. ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med 2021; NEJMoa2101544. Epub April 21, 2021. PMID:33882225 https://doi.org/10.1056/NEJMoa2101544.
13. Paden CR, Tao Y, Queen K, et al. Rapid, sensitive, full-genome sequencing of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020;26:2401-5. PMID:32610037 https://doi.org/10.3201/ eid2610.201800.
14. Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis 2021; ciab229. Epub March 10, 2021. PMID:33704435 https://doi.org/10.1093/cid/ciab229.
15. Enforde MW, Olson SM, Self WH, et al., IVY Network, HAIVEN Investigators. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged ? 65 years, United States, January-March 2021. MMWR Morb Mortal Wkly Rep 70:674-9, 2021. PMID:33956782 https://doi.org/10.15585/mmwr. mm7018e1.
16. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis 2021; ciab361. Epub April 26, 2021. PMID:33900384 https://doi.org/10.1093/cid/ciab361
17. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397:1819-29, 2021. PMID: 33964222 https:// doi.org/10.1016/S0140-6736 (21)00947-8.
18. Vaccine Breakthrough Infections Reported to CDC, United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 70:792-793, 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7021e3external icon.
19. Lipsitch M, Kahn R. Interpreting vaccine efficacy trial results for infection and transmission. Vaccine 39:4082-4088, 2021.
20. Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, Rescigno M. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19 J Clin Invest 2021; 131(12):e149154.
21. Chen M, Yuan Y, Zhou Y, Deng S, Zhao J, Feng F, Zou H, Sun C. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty 10:94, 2021.
22. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 21:e26-35, 2021.
23. Priyanka C, Choudhary P. Vaccine efficacy against COVID-19: A foresight on the host-associated factors Journal of the Formosan Medical Association 20:1405e1407, 2021.
24. Anbarasu A, Ramiah S, Livingnstone P. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality? Human Vaccines & Inmunotherapeutics 16(9):2217-2218, 2020.
25. Ruiz-Galiana J, Cantón R, De Lucas P, García A, García-Lledó A, Gómez J et al. Vacunación anti-COVID-19: La realidad tras los ensayos clínicos. Revista Española de Quimioterapia doi:10.37201/req/035.2021 - Advance Access published April 28, 2021.
26. Reina P, Fraile-Ribot S. Impact of spike genetic variants in vaccines against SARS-CoV-2. Vacunas 22(2):59-61, 2021.
27. Wibowo A. SIR modeling the dual disaster impacts of omicron b.1.1.529 and natural disaster events on simulated 6 months (December 2021 - May 2022) Healthcare System Resiliences in Fragile SE Asia Ring of Fire Ecosystems. Med Rxiv 2021.12.07.21267405; doi: https://doi.org/10.1101/2021.12.07.21267405.